Literature DB >> 25728989

Modified amelogenin is a new and versatile nanomaterial for biomedical applications.

Thomas Imhof1, Nora Gruenewald2, Guenter Schwarz2, Michael J Noack3, Manuel Koch4,5.   

Abstract

Amelogenin self-assembly is crucial for tooth biomineralization and crystallite enamel orientation. Amelogenin forms stable nanoparticles under physiological conditions. Here, we tested whether the surface properties and binding characteristics of these particles could be modified to enhance amelogenin function as a biomaterial. We evaluated different amelogenin fusion proteins for their ability to form hybrid nanoparticles. As a proof-of-concept, the integrin-binding tripeptide Arg-Gly-Asp (RGD) sequence from fibronectin was integrated into mouse amelogenin (rM179) at three different positions. Dynamic light scattering (DLS) measurements revealed that these amelogenin fusion proteins still form nanospheres. Additional DLS and isothermal titration calorimetry measurements showed that the mixtures of RGD-modified amelogenin and wild-type amelogenin form stable particles. We determined that insertion of the RGD-loop at the amelogenin C-terminus converts the nanoparticle into a cell-binding substrate. Calvarial osteoblasts efficiently attached and spread on modified amelogenin, whereas almost no binding was observed on wild-type amelogenin. These results establish amelogenin as a new versatile biomaterial that can be easily modified to add additional functions.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  RGD tripeptide; amelogenin; functionalization; fusion protein; nanoparticle

Mesh:

Substances:

Year:  2015        PMID: 25728989     DOI: 10.1002/bit.25576

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  1 in total

1.  TGF-β1 autocrine signalling and enamel matrix components.

Authors:  Saeko Kobayashi-Kinoshita; Yasuo Yamakoshi; Kazuo Onuma; Ryuji Yamamoto; Yoshinobu Asada
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.